These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 12416899)

  • 21. Interaction of i.v. anaesthetic agents with 5-HT3 receptors.
    Appadu BL; Lambert DG
    Br J Anaesth; 1996 Feb; 76(2):271-3. PubMed ID: 8777109
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytochrome P450 2D6 metabolism and 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting.
    Janicki PK
    Med Sci Monit; 2005 Oct; 11(10):RA322-8. PubMed ID: 16192915
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Prevention and treatment of postoperative nausea and vomiting with 5-HT3-receptor blockers].
    Alon E; Biro P
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1996 May; 31(4):200-4. PubMed ID: 8704077
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Are there differences among the serotonin antagonists?
    Tonato M; Roila F; Del Favero A
    Support Care Cancer; 1994 Sep; 2(5):293-6. PubMed ID: 8000725
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preclinical and clinical pharmacology of the 5-HT3 receptor antagonists.
    Wolf H
    Scand J Rheumatol Suppl; 2000; 113():37-45. PubMed ID: 11028830
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The efficacy and cost-effectiveness of prophylactic 5-hydroxytryptamine3 receptor antagonists: tropisetron, ondansetron and dolasetron.
    Paech MJ; Rucklidge MW; Banks SL; Gurrin LC; Orlikowski CE; Pavy TJ
    Anaesth Intensive Care; 2003 Feb; 31(1):11-7. PubMed ID: 12635388
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Granisetron: new insights into its use for the treatment of chemotherapy-induced nausea and vomiting.
    Tan M
    Expert Opin Pharmacother; 2003 Sep; 4(9):1563-71. PubMed ID: 12943486
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interaction of the antiemetics ondansetron and granisetron with the cytotoxicity induced by irradiation, epirubicin, bleomycin, estramustine, and cisplatin in vitro.
    Behnam Motlagh P; Henriksson R; Grankvist K
    Acta Oncol; 1995; 34(6):871-5. PubMed ID: 7576757
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Granisetron. A pharmacoeconomic evaluation of its use in the prophylaxis of chemotherapy-induced nausea and vomiting.
    Plosker GL; Benfield P
    Pharmacoeconomics; 1996 Apr; 9(4):357-74. PubMed ID: 10160110
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A network meta-analysis on the efficacy of serotonin type 3 receptor antagonists used in adults during the first 24 hours for postoperative nausea and vomiting prophylaxis.
    Tang DH; Malone DC
    Clin Ther; 2012 Feb; 34(2):282-94. PubMed ID: 22296947
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tropisetron: an update of its use in the prevention of chemotherapy-induced nausea and vomiting.
    Simpson K; Spencer CM; McClellan KJ
    Drugs; 2000 Jun; 59(6):1297-315. PubMed ID: 10882164
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-emetic effect of ondansetron and granisetron after exposure to mixed neutron and gamma irradiation.
    Martin C; Roman V; Agay D; Fatôme M
    Radiat Res; 1998 Jun; 149(6):631-6. PubMed ID: 9611102
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A review of granisetron, 5-hydroxytryptamine3 receptor antagonists, and other antiemetics.
    Hsu ES
    Am J Ther; 2010; 17(5):476-86. PubMed ID: 20844345
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy, safety and effectiveness of ondansetron compared to other serotonin-3 receptor antagonists (5-HT3RAs) used to control chemotherapy-induced nausea and vomiting: systematic review and meta-analysis.
    Simino GP; Marra LP; Andrade EI; Acúrcio Fde A; Reis IA; De Araújo VE; Cherchiglia ML
    Expert Rev Clin Pharmacol; 2016 Sep; 9(9):1183-94. PubMed ID: 27180992
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Granisetron: the second serotonin-receptor antagonist.
    Adams VR; Valley AW
    Ann Pharmacother; 1995 Dec; 29(12):1240-51. PubMed ID: 8672830
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of oral 5-HT3-receptor antagonists and low-dose oral metoclopramide plus i.m. dexamethasone for the prevention of delayed emesis in head and neck cancer patients receiving high-dose cisplatin.
    Mantovani G; Macciò A; Curreli L; Lampis B; Ghiani M; Bianchi A; Contu P
    Oncol Rep; 1998; 5(1):273-80. PubMed ID: 9458381
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 5-HT3 receptor antagonists do not alter spontaneous contraction of pregnant myometrium in vitro.
    Lin X; Du Y; Tang Y; Zeng K; Ni J; Liu J; Zhou J
    Int J Obstet Anesth; 2015 Feb; 24(1):41-5. PubMed ID: 25559472
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Recent improvements in antiemetic therapy].
    Roila F; Palladino MA; Ciccarese G; Basurto C
    Tumori; 1997; 83(2 Suppl):S3-14. PubMed ID: 9235727
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A risk-benefit assessment of serotonin 5-HT3 receptor antagonists in antineoplastic therapy-induced emesis.
    Perez EA
    Drug Saf; 1998 Jan; 18(1):43-56. PubMed ID: 9466087
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Serotonin and anticancer drug-induced emesis].
    Minami M; Endo T; Hamaue N; Hirafuji M
    Yakugaku Zasshi; 2004 Aug; 124(8):491-507. PubMed ID: 15297719
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.